Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax®-Direct Trial

BETHESDA, Md., Nov. 6 , 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio) a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has initiated a collaboration with Sarah Cannon Research UK and the Leaders in Oncology Care (LOC) on a Phase I/II trial with DCVax ^® -Direct for metastatic colon cancer.  Sarah Cannon Research UK is the UK arm of the Sarah Cannon Research Institute, which specializes in cancer drug development and has a network of more than 700 physicians in the US and UK. 

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Colon cancer is the second leading cause of cancer deaths (after lung cancer), exceeding even deaths from breast cancer or prostate cancers.  DCVax ^® -Direct offers an important potential new treatment option for colon cancer patients whose cancer has spread and is no longer operable. DCVax ^® -Direct is specifically designed to treat inoperable cancers in various tissues through direct injection into the tumors.  It can be injected into any number of tumors, and virtually any location in the body (with imaging guidance for interior tissues).  

As previously reported, the Company has received FDA approval for a 36-patient Phase I/II trial in any solid tumor cancers.  The primary endpoint of the trial will be a measure of tumor response (regression) in patients' existing, established tumors.  As part of the collaboration with Sarah Cannon Research UK and LOC, the Company will pursue UK regulatory approval of Phase I/II trials.

Sarah Cannon Research UK is the London-based arm of Sarah Cannon Research Institute (SCRI), a global strategic research organization focusing on advancing therapies and accelerating drug development.  It is one of the largest clinical research programs, conducting community-based clinical trials in oncology through a network of more than 700 physicians in the US and UK.  SCRI also has seven strategic oncology sites with over 200 investigators who see 75,000 new patients each year.

The Leaders in Oncology Care (LOC) was formerly known as the London Oncology Clinic, and is renowned in the UK as the leading private cancer center.  LOC is well known for its patient-centered focus, and its continuous innovation bringing the latest cutting edge technologies and new treatments to its patients. 

1 2 Next › Last »